Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Fresenius Biotech GmbH |
---|---|
Information provided by: | Fresenius Biotech GmbH |
ClinicalTrials.gov Identifier: | NCT00563836 |
Primary evaluation of the safety, tolerability and feasibility regarding specific postoperative complications of an adjuvant treatment with catumaxomab administered after tumor resection.
Condition | Intervention | Phase |
---|---|---|
Ovarian Cancer Epithelial Ovarian Cancer |
Drug: Catumaxomab |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | Multicenter, Single-Arm, Phase II Study of the Trifunctional Antibody Catumaxomab (Anti-EpCAM x Anti-CD3) Administered Intra- and Postoperatively in Patients With Epithelial Ovarian Cancer |
Estimated Enrollment: | 41 |
Study Start Date: | November 2007 |
Estimated Primary Completion Date: | November 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: Catumaxomab
10 µg Catumaxomab intraoperatively and 4 ascending doses (10, 20, 50 and 150 µg) on day 7, 10, 13 and 16
|
An open label, multi-center, single-arm, phase II study according to Fleming´s one-stage design. The surgical procedure on Day 0 will be performed according to AGO State of the Art, followed by one intraoperative and four postoperative intraperitoneal administrations of catumaxomab within 16 days. The Discharge Visit will be performed when the patient is leaving the hospital but not earlier than 1 day after the last infustion, followed by the End of Study Visit on Day 30.
Catumaxomab is a trifunctional antibody targeting EpCAM on tumor cells and CD3 on T cells. Trifunctional antibodies represent a new concept for targeted anticancer therapy. This new antibody class has the capability to redirect T cells and accessory cells (e.g. macrophages, dendritic cells [DCs] and natural killer [NK] cells) to the tumor site. According to preclinical data, trifunctional antibodies activate these different immune effector cells, which can trigger a complex anti-tumor immune response.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Fresenius Biotech GmbH ( Fresenius Biotech GmbH ) |
Study ID Numbers: | IP-CAT-OC-02 |
Study First Received: | November 23, 2007 |
Last Updated: | January 15, 2009 |
ClinicalTrials.gov Identifier: | NCT00563836 History of Changes |
Health Authority: | Germany: Paul-Ehrlich-Institut |
ovarian cancer catumaxomab phase II |
intraoperative adjuvant trifunctional antibody |
Ovarian Neoplasms Immunologic Factors Gonadal Disorders Adjuvants, Immunologic Genital Neoplasms, Female Endocrine System Diseases Urogenital Neoplasms Ovarian Diseases |
Ovarian Epithelial Cancer Genital Diseases, Female Antibodies Ovarian Cancer Endocrinopathy Endocrine Gland Neoplasms Immunoglobulins |
Ovarian Neoplasms Immunologic Factors Gonadal Disorders Physiological Effects of Drugs Genital Neoplasms, Female Endocrine System Diseases Urogenital Neoplasms Ovarian Diseases |
Pharmacologic Actions Adnexal Diseases Genital Diseases, Female Neoplasms Antibodies Neoplasms by Site Endocrine Gland Neoplasms |